Objective-Bone morphogenic protein 4 (BMP4) is an important mediator of endothelial dysfunction in cardio-metabolic diseases, whereas platelet-derived growth factors (PDGFs) are major angiogenic and proinflammatory mediator, although the functional link between these 2 factors is unknown. The present study investigated whether PDGF mediates BMP4induced endothelial dysfunction in diabetes mellitus. Approach and Results-We generated Ad-Bmp4 to overexpress Bmp4 and Ad-Pdgfa-shRNA to knockdown Pdgfa in mice through tail intravenous injection. SMAD4-shRNA lentivirus, SMAD1-shRNA, and SMAD5 shRNA adenovirus were used for knockdown in human and mouse endothelial cells. We found that PDGF-AA impaired endothelium-dependent vasodilation in aortas and mesenteric resistance arteries. BMP4 upregulated PDGF-AA in human and mouse endothelial cells, which was abolished by BMP4 antagonist noggin or knockdown of SMAD1/5 or SMAD4. BMP4-impared relaxation in mouse aorta was also ameliorated by PDGF-AA neutralizing antibody. Tail injection of Ad-Pdgfa-shRNA ameliorates endothelial dysfunction induced by Bmp4 overexpression (Ad-Bmp4) in vivo. Serum PDGF-AA was elevated in both diabetic patients and diabetic db/db mice compared with nondiabetic controls. Pdgfa-shRNA or Bmp4-shRNA adenovirus reduced serum PDGF-AA concentration in db/db mice. PDGF-AA neutralizing antibody or tail injection with Pdgfa-shRNA adenovirus improved endothelial function in aortas and mesenteric resistance arteries from db/db mice. The effect of PDGF-AA on endothelial function in mouse aorta was also inhibited by Ad-Pdgfra-shRNA to inhibit PDGFRα. Conclusions-The present study provides novel evidences to show that PDGF-AA impairs endothelium-dependent vasodilation and PDGF-AA mediates BMP4-induced adverse effect on endothelial cell function through SMAD1/5and SMAD4-dependent mechanisms. Inhibition of PGDF-AA ameliorates vascular dysfunction in diabetic mice. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/This study found that platelet-derived growth factor-AA is an important downstream effector in endothelial cell dysfunction induced by cardiovascular risk factor bone morphogenic protein-4. Platelet-derived growth factor-AA increases in diabetes mellitus. Inhibition of plateletderived growth factor-AA improves vascular function in diabetic mice, suggesting that platelet-derived growth factor-AA may be a critical mediator in vascular dysfunction of diabetes mellitus.
B one morphogenic protein 4 (BMP4), which falls into the transforming growth factors-β (TGF-β) superfamily, plays an essential role in cartilage formation, bone mineralization, and early embryonic development. 1 BMP4 and BMP2 both bind to the BMPRII, which then dimerize with BMPRI. The dimerization and phosphorylation of BMPRI leads to the activation of canonical Smad1/5/8 in the cytoplasm. 2 Smad1/5/8 associates with co-Smad, Smad4, and translocate to the nucleus. This Smad complex will bind to the Smadresponsive element and induce the transcription of Smad-target genes. 3 In addition to the canonical Smad signaling, BMP4 also activates ERK (extracellular signal-regulated kinases) and p38/JNK non-Smad pathway in certain cell types for finetuning of its action. 3, 4 In the cardiovascular system, mutations or anomalies of BMP are associated with the development of pulmonary hypertension, cardiovascular calcification, stroke, and type 2 diabetes mellitus. 5 In the vasculature, BMP4 acts as a proinflammatory cytokine to stimulate superoxide anion production and exerts inflammatory effects through NADPH oxidases. BMP4 expression is upregulated in human calcified atherosclerotic plaques, 6 and oscillatory sheer stress induces endothelial expression of BMP4. 7 BMP4 increases the expression and activity of cyclooxygenase-2 and, in turn, the production of vasoconstrictive prostanoids to impair endothelial function in arteries from rats, mice, and human. 8 BMP4 also induces endothelial cell apoptosis through oxidative stress, 9 and it stimulates protein carbonylation involved in endothelial dysfunction. 10 BMP4 enhances foam cell formation by stimulating BMPRII/Smad1/5/8 signaling and accelerating the progression of atherosclerosis. 11 In vivo inhibition of BMP4 restores endothelial function in diabetic db/db mice. 12 As one of numerous growth factors, platelet-derived growth factor (PDGF) was originally identified as platelets and serum mitogen for fibroblasts, smooth muscle cells (SMC), and glial cells. 13 PDGFs can also be secreted by endothelial cells, SMC, and fibroblast. 14 The protein PDGFA and PDGFB can dimerize to form PDGF-AA, PDGF-BB, and PDGF-AB. PDGF has 2 receptors PDGFRα and PDGFRβ, which also form dimer through noncovalent binding. 15 The PDGF:PDGFR interaction is described as one protein from the dimer binds to one receptor from the dimerized receptor. Both PDGF-AA and PDGF-BB can bind to PDGFRα, whereas PDGFRβ is only activated by PDGF-BB. 16 PDGFs and PDGF receptors are among the major angiogenic regulators that involve in the development of arteriosclerosis, hypertension, and diabetes mellitus. PDGF promotes SMC proliferation in human arteriosclerosis lesions. 17 Inhibition of PDGF receptors prevents cardiac allograft arteriosclerosis in cholesterol-fed rabbits. 18 PDGF-A and -B chain products participate coordinately and sequentially in hypoxic pulmonary vascular remodeling. 19 Increased plasma PDGF is found in hypertensive patients. In pulmonary arterial hypertension, the expression and phosphorylation of PDGF receptor are increased. 20 In type 1 diabetes mellitus, serum PDGF-BB is elevated. 21 In type 1 diabetic mice with hindlimb ischemia, PDGF-BB is downregulated and PDGF-BB supplement improves blood flow and recovery. 22 In human diabetic nephropathy, PDGF is upregulated in renal biopsies. 23 Both BMP4 and PDGF are proinflammatory and present in human atherosclerotic lesions; therefore, we want to investigate whether there is a possible association between them in the context of endothelial dysfunction in diabetes mellitus and whether BMP4-induced vascular dysfunction is mediated by PDGF.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

PDGF-AA Impairs Endothelium-Dependent Vasodilation
Ex vivo treatment of PDGF-AA (200 ng/mL, 24 hours) reduced endothelium-dependent relaxation (EDR) induced by acetylcholine in isolated C57BL/6J mouse aorta, which can be reversed by anti-PDGF-AA neutralizing antibody (2 μg/ mL; Figure 1A and 1B) without altering sodium nitroprusside (SNP)-induced EDR ( Figure IA in the online-only Data Supplement). We found similar effects on db/m + aorta (data not shown). PDGF-AA also impairs flow-mediated vasodilation in pressurized mesenteric resistance arteries from C57BL/6J mice ( Figure 1C and 1D). To examine whether the effect of PDGF-AA is mediated through PDGFRα, we constructed Ad-Pdgfra-shRNA adenoviral vector to knockdown PDGFRα by tail injection in mice. Successful knockdown was confirmed by protein and mRNA expression in mouse aorta ( Figure 2D and 2E). We found that the effect of PDGF-AA on EDRs of mouse aorta was abolished by Ad-Pdgfra-shRNA treatment ( 
BMP4 Upregulated PDGF-AA Expression in Endothelial Cells
Previously, we found that BMP4 can cause vascular dysfunction 8 ; therefore, we propose whether PDGF-AA acts along the same pathway. In human umbilical vein endothelial cells (HUVECs), BMP4 upregulated PDGF-AA at both mRNA ( Figure 3A and 3B) and protein level ( Figure 3E ), which can be abolished by noggin ( Figure 3C ), without affecting PDGF-BB expression ( Figure IIA in the online-only Data Supplement). PDGF-AA can also be found in secreted form from medium exposed to HUVECs treated with BMP4 ( Figure 3D ), whereas PDGF-BB level remained similar ( Figure IIB and IIC in the online-only Data Supplement). BMP4 also upregulated PDGFRα at mRNA and protein level ( Figure IID and IIE in the online-only Data Supplement). BMP2 did not induce PDGFA expression ( Figure IIF in the online-only Data Supplement). As BMP4 is known to activate Smad1/5 and induce Smad4 translocation to induce Smad4 target gene transcription, 4 we tested whether PDGFA expression is dependent on Smad pathway. BMP4 induced Smad1/5 phosphorylation in HUVECs ( Figure 3F ; Figure Figure  3H ). Transfection efficiency was also verified at mRNA level ( Figure IIIE in the online-only Data Supplement). These results indicate that BMP4 upregulates PDGF-AA through Smad1/5 and Smad4 pathway. As a complementary approach, we also constructed SMAD1/5 and SMAD4 overexpression to see whether upregulation of Smad increases PDGF-AA. Indeed, Ad-SMAD1/5 or Ad-SMAD4 increased PDGF-AA protein expression in HUVECs ( Figure 3I ; Figure IIIF -IIII in the online-only Data Supplement). These data showed that in both human and mouse endothelial cells, BMP4-induced PDGF-AA upregulation is mediated through the canonical Smad1/5 and Smad4 signaling. 
BMP4 Impairs Endothelium-Dependent Vasodilation Through Upregulation of PDGF-AA
Previously, we showed that BMP4 causes endothelial dysfunction. 8 We wonder whether PDGF-AA mediates such effect.
To study this, we tested first on isolated aorta in ex vivo tissue explant culture. BMP4-impaired EDR in mouse aorta was improved by neutralizing antibody against PDGF-AA ( Figure 4A and 4B) , without affecting SNP-induced relaxation ( Figure IVA in the online-only Data Supplement). Adenoviral Pdgfa-shRNA in vivo treatment also alleviated BMP-impaired EDR ( Figure 4C ).To further verify this effect, we did intravenous injection of adenoviral-Bmp4 to overexpress BMP4 in vivo, together with Ad-Pdgfa-shRNA to knockdown PDGF-AA. We found that Ad-Bmp4 impaired EDR, whereas Ad-Pdgfa-shRNA restored EDRs impaired after Ad-Bmp4 treatment ( Figure 4D and 4E) without affecting SNPinduced relaxation ( Figure 4F ). In addition, we showed that upregulation of PDGF-AA protein ( Figure 4H ; Figure IVB and IVC in the online-only Data Supplement) and PDGF-AA staining in the aortic endothelium ( Figure 4G ; Figure IVD and IVE) by Ad-Bmp4, which decreased with Ad-Pdgfa-shRNA.
Upregulation and Function of PDGF-AA in Diabetic Vascular Dysfunction
We showed that BMP4 upregulates PDGF-AA. BMP4 is also involved in endothelial dysfunction of db/db mice. 12 Here we tested whether PDGF-AA is a risk factor leading to endothelial dysfunction in db/db mice as well. We found higher plasma level of PDGF-AA in diabetic patients (fasting glucose >7.0 mmol/L) compared with nondiabetic subjects ( Figure  5A ), whereas PDGF-BB levels were similar ( Figure VA in the online-only Data Supplement). Plasma PDGF-AA, but not PDGF-BB ( Figure VB in the online-only Data Supplement), was also higher in db/db mice compared with db/m + , which reduced with knockdown of Bmp4 by Ad-Bmp4-shRNA or knockdown of Pdgfa by Ad-Pdgfa-shRNA ( Figure 5B ). Aorta from db/db mice also secreted more PDGF-AA than db/m + (Figure 5C ). However, expressions of Pdgfb, Pdgfra, and Pdgfrb were comparable in db/db and db/m + mice ( Figure  VC -VE in the online-only Data Supplement). Inhibition of PDGF-AA by neutralizing antibody improved EDRs in isolated aorta from db/db mice ( Figure 5D and 5E). Then we inhibited PDGFA by intravenous injection of Ad-Pdgfa-shRNA in db/db mice. Upregulation of PDGF-AA at mRNA level ( Figure 5H ) and protein level ( Figure 5I and 5J) in aorta from db/db mice was suppressed after Ad-Pdgfa-shRNA treatment. To confirm the knockdown efficiency in endothelial cells in vivo, pulmonary endothelial cells and aortic endothelial cells were also isolated from db/m + mice injected with Ad-Pdgfa-shRNA to show the inhibition of PDGF-AA at protein and mRNA levels ( Figure VI and VJ) . Glucose tolerance and insulin tolerance were similar between Ad-GFP (as control) and Ad-Pdgfa-shRNA-treated mice ( Figure VG and VH in the online-only Data Supplement). EDRs in db/ db aorta were improved after Ad-Pdgfa-shRNA in vivo treatment ( Figure 5F-G) , whereas SNP-induced relaxations were unchanged ( Figure VF in the online-only Data Supplement). Flow-mediated vasodilation was significantly smaller in resistance mesenteric arteries from db/db mice ( Figure 6C ) compared with those from db/m + injected with Ad-GFP ( Figure  6A ), whereas the vessel diameter, pressure-induced dilation (from 20 to 80 mm Hg), and Phe-induced contraction were comparable. Injection with Ad-Pdgfa-shRNA significantly improved flow-mediated vasodilation in db/db mice ( Figure  6D ), whereas flow-mediated vasodilation in db/m + mice treated with Ad-Pdgfa-shRNA was similar ( Figure 6B ). Data are summarized in Figure 6E .
Discussion
BMP4 is identified as a new risk factor in cardiovascular disease, 3 particularly showing harmful effects on endothelial cell function, but the critical effector of BMP4 is still unclear.
Previous study has shown that BMP4 upregulates cyclooxygenase-2 expression and alters vascular reactivity. 8 Higher dosage of BMP4 will also cause cell apoptosis. 9 The present study demonstrates that PDGF-AA mediates BMP4 signaling and its harmful effects on endothelial cells through the canonical Smad1/5 and Smad4 pathway. Importantly, PDGF-AA is upregulated in diabetes mellitus. Knockdown of PDGF-AA in vivo by Ad-Pdgfa-shRNA can abolish BMP4-induced endothelial dysfunction in nondiabetic mice, while also improved endothelial function in diabetic db/db mice, indicating PDGF-AA as a critical effector of BMP4 contributing to vascular dysfunction in diabetes mellitus.
PDGFs and their receptors have served as prototypes for growth factor and receptor tyrosine kinase function for >25 years. PDGF-AA expression correlates with elevated pressure and arterial wall hypertrophy. 24 Long-term PDGF treatment in organ-cultured rabbit mesenteric artery can impair EDR. 25 PDGF, although first identified in platelet, can also be secreted from endothelial cells, fibroblasts, and SMCs. 14 In fact, PDGF is believed to participate in SMC proliferation and arteriosclerosis. However, little is known on whether and how PDGF-AA exhibits beneficial/harmful effect on endothelial cells. Early study showed that PDGF-BB can dilate rat aorta and mesenteric arteries. 26 However, we found that PDGF-AA impairs endothelium-dependent vasodilation. The difference may be caused by the differential expressions of PDGFRα and PDGFRβ in different vascular bed and different downstream signaling pathways. BMP4 upregulates PDGF-AA, but not PDGF-BB, and PDGF-AA mediates the effect of BMP4 on endothelial function. The newly discovered PDGF-CC and PDGF-DD are secreted as disulphidelinked homodimers, and they require proteolytic removal of the N-terminal CUB domain for receptor binding and activation. 27 However, because of their scarce expression in the vasculature, we did not test the function of PDGF-CC/DD in the present study.
Our previous study showed that BMP4 causes endothelial dysfunction in db/db mice. 12 Here we also found increase of plasma PDGF-AA in diabetic human and db/db mice. Importantly, we found that antagonizing PDGF-AA improves endothelium-dependent vasodilation in db/db mice, 12 indicating PDGF-AA as a new risk factor to cause vascular dysfunction. We also showed that inhibition of Smad1/5 and Smad4 abolished BMP4-induced PDGF-AA. Smads are intracellular proteins that transduce extracellular signals from TGF-β and BMPs to the nucleus to activate target gene transcription. Studies have shown the role of TGF-β/Smad3 in diabetes mellitus. Targeting TGF-β/Smad3 and its downstream effectors can be an effective strategy for the treatment of renal fibrosis in diabetes mellitus. 28 Smad3 also regulates pancreatic β-cell function and proliferation. 29 In addition, TGF-β/Smad3 is involved in white adipose tissue expansion, and blockade of Smad3 protects against obesity and diabetes mellitus. 30 However, the role of BMP4/Smad is more complicated in diabetes mellitus. Inhibition of BMP4/Smad1 attenuates diabetic nephropathy. 31 BMP4 reduces glucose-stimulated insulin secretion in pancreatic β-cell. 32 On the contrary, in adipocytes, BMP4 induces white-to-brown phenotypic, which improves glucose metabolism and inhibits hypertrophic obesity. 33, 34 Here we showed that BMP4-Smad-PDGF-AA signaling is clearly harmful on the vasculature of diabetic mice. Although we did not see change of glucose metabolism with Ad-Pdgfa-shRNA in vivo treatment, we cannot exclude the effect of PDGF-AA on metabolic organs, such as pancreas and adipose tissue. In addition, although PDGF-AA impairs vasodilation, PDGF also enhances angiogenesis, which is believed to be beneficial for wound healing in diabetes mellitus. Therefore, PDGF-AA might demonstrate differential effect in different tissues and disease model.
Diabetes mellitus is among the most prevalent diseases in modern society. Therefore, a clear understanding of the underlying mechanisms of diabetes mellitus promotes the discovery of new therapeutics. Our current study added proof of the functional importance of BMP4 in diabetes mellitus by identifying its downstream effector and a secretory molecule PDGF-AA that directly impairs nitric oxide-dependent vasodilation in diabetic mice. This finding adds more information for us to understand the complex picture of how cardiovascular risk factors cause vascular complications in diabetes mellitus and obesity.
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